ClinicalTrials.gg
Active, not recruitingNCT04728633Updated May 6, 2026

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

A Phase 2 interventional study of Carmustine and Ethiodized Oil in Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma and Stage IV Choroidal and Ciliary Body Melanoma AJCC V8, sponsored by Thomas Jefferson University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Thomas Jefferson University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 191 studies in Uveal Melanoma with a site in United States — 26 open to participants now, 51 under way, 7 of them phase 3. Uveal Melanoma · United States.

Enrollment
96th of 163
28 · median 36
Started
2021
with 11 others
Phase 2
79 of 191
7 open now
Primary completion
2027-01
later than 15 of 50 live
Registered
142nd of 191
by date
Lead sponsor
5 of 191
Thomas Jefferson University

Among the 191 studies in Uveal Melanoma with a site in United States, this one is the 96th largest by enrollment of the 163 interventional ones that give a count, is one of 12 that started in 2021, is one of 79 in phase 2, reaches primary completion later than 15 of the 50 other live ones, and was the 142nd registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

26 of the 191 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Uveal Melanoma with a site in United States, or all of them as a file.
02

Study summary

This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases). Transarterial chemoembolization involves the injection of a blocking agent (gelatin sponge, ethiodized oil) and a chemotherapy agent (carmustine) directly into the artery in the liver to treat liver cancers. Chemotherapy drugs, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. transarterial chemoembolization with carmustine in combination with ethiodized oil and gelatin sponge may help cause the tumors in the liver to shrink or disappear.

Read the detailed description

PRIMARY OBJECTIVE:

To determine the efficacy (clinical response) in terms of disease control rate (DCR) (complete response [CR] + partial response [PR] + stable disease [SD]) with chemoembolization of hepatic metastases with 300 mg of carmustine (BCNU) in ethiodized oil in metastatic uveal melanoma patients.

SECONDARY OBJECTIVES:

To investigate overall survival (OS) and progression-free survival (PFS) in uveal melanoma patients with hepatic metastases.

To assess the toxicity of the above treatment regimen.

OUTLINE:

Patients undergo transarterial chemoembolization (TACE) by receiving an infusion of carmustine dissolved in ethiodized oil and an injection of gelatin sponge. Treatment repeats once every 4 weeks (Q4W) for bilobar disease or once every 7 weeks (Q7W) for unilobar disease in the absence of disease progression or unacceptable toxicity or until maximum clinical benefit is obtained.

Steroid taper will begin the day of patient discharge. After completion of study treatment, patients are followed up at 30 days, and then every 2 months for up to 2 years.

After 3 years from first treatment, follow-up scans may occur every 16-20 weeks and labs every other month.

03

Conditions studied

  • Metastatic Malignant Neoplasm in the Liver
  • Metastatic Uveal Melanoma
  • Stage IV Choroidal and Ciliary Body Melanoma AJCC V8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed uveal melanoma in the liver
  • Tumor burden \< 75%. Patients must have at least one tumor measuring >= 10 mm in longest diameter by magnetic resonance imaging (MRI) or triphasic computed tomography (CT) (if MRI is not available or )
  • No prior transarterial catheter-directed therapies. Prior hepatic tumor ablation, hepatic radiation or liver resection will be permitted as long as growing measurable liver tumors exists. Prior systemic treatments are allowed as long as there are no outstanding toxicities greater than grade 1
  • Willingness and ability to give
  • (ECOG) performance status of 0-1
  • Serum creatinine =\< 2.0 mg/dl
  • =\< 2.0 mg/ml. Exceptions will be made for patients with diagnosed Gilbert's Syndrome. In this instance, a bilirubin level =\< 3.0 mg/ml will be allowed for this patients with this syndrome
  • Albumin >= 3.0 g/dl
  • No ascites
  • Granulocyte count >= 1500/m\^3
  • count >= 150,000/m\^3

Exclusion criteria

Exclusion Criteria:

  • Less than 18 years of age
  • Previous liver-directed treatments including immunoembolization, chemoembolization, radioembolization, hepatic arterial perfusion, or drug-eluting beads
  • Presence of life-limiting extrahepatic that requires systemic treatment within 3 months. However, radiation treatment of extrahepatic metastases such as bone, lymph nodes or subcutaneous metastases will be permitted while the patient is on study. Zometa or X-Geva to treat bone metastases will also be permitted. Immune check-point inhibitors while on study will NOT be permitted
  • Portal vein occlusion, or inadequate collateral portal venous flow, as determined by MRI
  • Known active viral or hepatitis requiring treatments with serum glutamic oxaloacetic transaminase () and serum glutamic pyruvic transaminase (SGPT) equal or greater than 5 times normal
  • Presence of uncontrolled hypertension or congestive heart failure, or acute myocardial infarction within 6 months of entry
  • Presence of any other medical conditions that imply a survival of less than six months
  • Uncontrolled severe bleeding tendency or active gastrointestinal (GI) bleeding due to varices or main portal vein occlusion. Abnormal coagulation test must be corrected prior to the procedure
  • History of life-threatening allergic reaction to iodinated contrast or BCNU despite pre-treatment with
  • Pregnant and/or breastfeeding women
  • Presence of known untreated . If patients have had previous treatment for brain metastasis, an MRI or CT of the brain must confirm the stabilization of the brain metastasis for more than 4 weeks
  • Biliary obstruction, biliary stent, or prior biliary surgery including sphincterotomy but excluding cholecystectomy
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Treatment (carmustine, ethiodized oil, gelatin sponge)

    Patients undergo TACE by receiving an infusion of carmustine dissolved in ethiodized oil and an injection of gelatin sponge. Treatment repeats Q4W for bilobar disease or Q7W for unilobar disease in the absence of disease progression or unacceptable toxicity or until maximum clinical benefit is obtained.

    Drug: Carmustine · Drug: Ethiodized Oil · Procedure: Transarterial Chemoembolization · Other: Medical Device Usage and Evaluation

Interventions

  • Given via infusion

    Also known as: 1,3-Bis(2-chloroethyl)-1-nitrosourea, 1,3-Bis(beta-chloroethyl)-1-nitrosourea, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, WR-139021, SRI 1720, SK 27702, Nitrumon, Nitrourean, N,N''-Bis(2-chloroethyl)-N-nitrosourea, FDA 0345, Carmustinum, Carmustin, steroid taper initiated on day of discharge

  • Given via infusion

    Also known as: Lipiodol, Iodized Oil, Ethiodol, ETHIODIZED OIL,, 8008-53-5

  • ProcedureTransarterial Chemoembolization

    Undergo TACE

    Also known as: TACE

  • OtherMedical Device Usage and Evaluation

    Given gelatin sponge via injection

06

What researchers measure

Primary outcomes

  1. Best response to treatment

    Response to treatment

    Time frame: After the completion of cycle 2 of chemoembolization (1 cycle = 4 or 7 weeks)

  2. Disease control rate (DCR) including complete response + partial response + stable disease

    All estimates of rates (e.g., DCR) will be presented with corresponding confidence intervals. For DCR, the method of Atkinson and Brown will be used to allow for the two-stage design using the criteria adapted from the international criteria proposed by Response Evaluation Criteria in Solid Tumors 1.03.

    Time frame: Up to 2 years

Secondary outcomes

  1. Time to progression

    Will be estimated by the Kaplan-Meier method.

    Time frame: From the first chemoembolization to the time when progression of liver metastases is confirmed, assessed up to 2 years

  2. Overall survival

    Will be estimated by the Kaplan-Meier method. Date and cause of death will be recorded. The cause of death will be categorized as either cancer-related or cancer unrelated.

    Time frame: From the first chemoembolization until death, assessed up to 2 years

07

Study locations

1 site
  • Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy
    Philadelphia, Pennsylvania 19107, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Jan 2027, 64 months after the start.

Of 39 non-industry phase 2 interventional studies under Uveal Melanoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 95. This study's planned 64 months is above that.

Counting every sponsor, half of 46 studies reached it within 52 months; a quarter within 37 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2021
First posted
Jan 28, 2021
StartActual
Sep 27, 2021
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jun 30, 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04728633
Responsible party
Sponsor
First posted
Jan 28, 2021
Start date
Sep 27, 2021
Primary completion
Jan 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 6, 2026

Study contacts

Carin Gonsalves, MD
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carmustine · Ethiodized Oil

Start the discussion